Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape
Science Advances · 2025
DOI: 10.1126/sciadv.adu0718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Fangqiang Zhu und 44 weiteren Autor:innen. Beteiligte Einrichtung: Biosciences and Biotechnology Division, Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Antibodies, Viral, Antibodies, Neutralizing. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Most previously authorized clinical antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have lost neutralizing activity to recent variants due to rapid viral evolution. To mitigate such escape, we preemptively enhance AZD3152, an antibody authorized for prophylaxis in immunocompromised individuals. Using deep mutational scanning (DMS) on the SARS-CoV-2 antigen, we identify AZD3152 vulnerabilities at antigen positions F456 and D420. Through two iterations of computational antibody design that integrates structure-based modeling, machine-learning, and experimental validation, we co-optimize AZD3152 against 24 contemporary and previous SARS-CoV-2 variants, as well as 20 potential future escape variants. Our top candidate, 3152-1142, restores full potency (100-fold improvement) against the more recently emerged XBB.1.5+F456L variant that escaped AZD3152, maintains potency against previous variants of concern, and shows no additional vulnerability as assessed by DMS. This preemptive mitigation demonstrates a generalizable approach for optimizing existing antibodies against potential future viral escape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biosciences and Biotechnology Division, Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
- Biologics Engineering, R&D, AstraZeneca, Gaithersburg, MD 20878, USA.
- Computational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
- Global Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
- Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.
- Chinese Academy of Medical Science (CAMS) Oxford Institute, University of Oxford, Oxford OX3 7BN, UK.
ORCID-Profile: Fangqiang Zhu, Saravanan Rajan, Ka Yin Kwong, Andre R Goncalves, Adam T Zemla, Edmond Y Lau, Yi Zhang, Yingyun Cai, Mikel Landajuela, Michael Kierny, Andrew Dippel, Bismark Amofah, Gilad Kaplan, Vanessa Cadevilla Peano, Ben Sparklin, Vancheswaran Gopalakrishnan, Kevin M Tuffy, Amy Nguyen, Gustavo Kijak, Aiste Dijokaite-Guraliuc, Gavin R Screaton, Brenden K Petersen, Thomas A Desautels, Simone Conti, Brent W Segelke, Emilia A Grzesiak, Felipe Leno da Silva, Thomas W Bates, Shivshankar Sundaram, Mark T Esser, Joseph R Francica, Daniel M Faissol
Zitieren
APA
Zhu, F., Rajan, S., Hayes, C. F., Kwong, K. Y., Goncalves, A. R., Zemla, A. T., Lau, E. Y., Zhang, Y., Cai, Y., Goforth, J. W., Landajuela, M., Gilchuk, P., Kierny, M., Dippel, A., Amofah, B., Kaplan, G., Cadevilla Peano, V., Morehouse, C., Sparklin, B., …, & LLNL Generative Unconstrained Intelligent Drug Engineering (GUIDE) consortium (2025). Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape. Science Advances. https://doi.org/10.1126/sciadv.adu0718
Vancouver
Zhu F, Rajan S, Hayes CF, Kwong KY, Goncalves AR, Zemla AT, et al. Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape. Science Advances. 2025. doi:10.1126/sciadv.adu0718
BibTeX
@article{Zhu2025,
author = {Zhu, Fangqiang and Rajan, Saravanan and Hayes, Conor F and Kwong, Ka Yin and Goncalves, Andre R and Zemla, Adam T and Lau, Edmond Y and Zhang, Yi and Cai, Yingyun and Goforth, John W and Landajuela, Mikel and Gilchuk, Pavlo and Kierny, Michael and Dippel, Andrew and Amofah, Bismark and Kaplan, Gilad and Cadevilla Peano, Vanessa and Morehouse, Christopher and Sparklin, Ben and Gopalakrishnan, Vancheswaran and Tuffy, Kevin M and Nguyen, Amy and Beloor, Jagadish and Kijak, Gustavo and Liu, Chang and Dijokaite-Guraliuc, Aiste and Mongkolsapaya, Juthathip and Screaton, Gavin R and Petersen, Brenden K and Desautels, Thomas A and Bennett, Drew and Conti, Simone and Segelke, Brent W and Arrildt, Kathryn T and Kaul, Samantha and Grzesiak, Emilia A and da Silva, Felipe Leno and Bates, Thomas W and Earnhart, Christopher G and Hopkins, Svetlana and Sundaram, Shivshankar and Esser, Mark T and Francica, Joseph R and Faissol, Daniel M and LLNL Generative Unconstrained Intelligent Drug Engineering (GUIDE) consortium, LLNL Generative Unconstrained Intelligent Drug Engineering (GUIDE) consortium},
title = {Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adu0718}
}
EUVIMED